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Chronic lymphocytic leukaemia (CLL), the most frequent leuk-
aemia in adults in Western countries, is a heterogeneous disease
with variable clinical presentation and evolution1,2. Two major
molecular subtypes can be distinguished, characterized respectively
by a high or low number of somatic hypermutations in the variable
region of immunoglobulin genes3,4. The molecular changes leading
to the pathogenesis of the disease are still poorly understood. Here
we performed whole-genome sequencing of four cases of CLL and
identified 46 somatic mutations that potentially affect gene func-
tion. Further analysis of these mutations in 363 patients with CLL
identified four genes that are recurrently mutated: notch 1
(NOTCH1), exportin 1 (XPO1), myeloid differentiation primary
response gene 88 (MYD88) and kelch-like 6 (KLHL6). Mutations
in MYD88 and KLHL6 are predominant in cases of CLL with
mutated immunoglobulin genes, whereas NOTCH1 and XPO1
mutations are mainly detected in patients with unmutated immu-
noglobulins. The patterns of somatic mutation, supported by func-
tional and clinical analyses, strongly indicate that the recurrent
NOTCH1, MYD88 and XPO1 mutations are oncogenic changes
that contribute to the clinical evolution of the disease. To our know-
ledge, this is the first comprehensive analysis of CLL combining
whole-genome sequencing with clinical characteristics and clinical
outcomes. It highlights the usefulness of this approach for the iden-
tification of clinically relevant mutations in cancer.
To gain insights into the molecular alterations that cause CLL, we
performed whole-genome sequencing of four cases representative of
different forms of the disease: two cases, CLL1 and CLL2, with no
mutations in the immunoglobulin genes (IGHV-unmutated) and two
cases, CLL3 and CLL4, withmutations in these genes (IGHV-mutated)
(Supplementary Table 1 and Supplementary Information). We used a
combination of whole-genome sequencing and exome sequencing, as
well as long-insert paired-end libraries, to detect variants in chromo-
somal structure (Supplementary Fig. 1 and Supplementary Tables 2–5).
We obtained more than 99.7% concordance between whole-genome
sequencing calls and genotyping data, indicating that the coverage and
parameters used were sufficient to detect most of the sequence variants
in these samples (Supplementary Information). We detected about
1,000 somatic mutations per tumour in non-repetitive regions
(Fig. 1a, Supplementary Fig. 2 and Supplementary Table 6). These
numbers of somatic mutations were lower than the numbers in mela-
noma and lung carcinoma5,6, but in agreement with previous estimates
of less than onemutationpermegabase (Mb) for leukaemias7. Themost
common substitution was the transition G.A/C.T, usually occurring
in a CpG context (Fig. 1b and Supplementary Fig. 2). We also detected
marked differences in the mutation pattern between CLL samples and
these differences were associated with tumour subtype (Fig. 1b). Thus,
IGHV-mutated cases showed a higher proportion ofA.C/T.Gmuta-
tions than cases with unmutated IGHV (166 0.2% versus 6.26 0.1%).
The basepreceding the adenine inA toC transversions showedanover-
representation of thymine, when compared to the prevalence expected
from its representation in non-repetitive sequences in the wild-type
genome (P, 0.001, Fig. 1c), and there were fewer A toC substitutions
at GpA dinucleotides than would be expected by chance (P, 0.001).
These differences between CLL subtypes might reflect the molecular
mechanisms implicated in their respective development. The pattern
and context of mutations are consistent with their being introduced by
the error-prone polymerase g during somatic hypermutation in
immunoglobulin genes8. This indicates that polymerase g could con-
tribute to the high frequency of A.T to C.G transversions in cases
with IGHV-mutated. It also extends the differences observed between
these two CLL subtypes to the genomic level.
We classified the somatic mutations into three different classes
according to their potential functional effect (Supplementary Informa-
tion). We also searched for small insertions and deletions (indels) in
coding regions: we found and validated five somatic indels, which
caused frameshifts in protein-coding regions (Supplementary Table 7).
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We identified 46mutations that changed the protein-coding sequences
of 45 genes in the four patients analysed (Supplementary Table 7).
None of these nucleotide substitutions had been previously linked to
CLL and among the five indel mutations, only one, in NOTCH1
(p.P2515Rfs*4), had been previously found in various lymphoid
malignancies, including CLL9,10. To determine whether any of these
45 geneswasmutated inmore thanoneCLLcase,we analysed an initial
validation set of 169 CLL patients.We focused on the 26 genes that are
expressed at the RNA level in CLL cells (Supplementary Table 7)
because mutations in expressed genes are more likely to have a bio-
logical effect than those in non-expressed genes. We used a pooled-
sequencing strategy that led us to identify four genes with at least one
additional mutation in the validation series: these were NOTCH1,
MYD88, XPO1 andKLHL6 (Table 1 and Supplementary Information).
Analysis of additional CLL cases revealed that the deletion of a CT
dinucleotide in NOTCH1 (p.P2515Rfs*4) was found in 29 of 255
patients and two additional mutations in the same region were also
found (p.Q2503* and p.F2482Ffs*2) (Fig. 2a, b). Accordingly,
NOTCH1 is mutated in 12% of CLL patients (Supplementary Table
8). These mutations generate a premature stop codon, resulting in a
NOTCH1 protein lacking the C-terminal domain, which contains a
PEST sequence (a sequence rich in proline, glutamic acid, serine and
threonine) (Fig. 2a). Removal of this region results in the accumulation
of an active protein isoform in the mutated CLL cells (Fig. 2c and
Supplementary Fig. 3). NOTCH1 is constitutively expressed in
CLL11, but the NOTCH1 mutations identified herein generate a more
stable and active isoform of the protein. Gene expression analysis of
ten NOTCH1-mutated and 49 unmutated CLL cases revealed a high
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Figure 1 | Profile of somaticmutations in fourCLL genomes. a, Distribution
of somatic alterations. For each tumour genome, copy number (solid lines),
density of mutations per 5-Mb window (bars) and protein-coding mutations
(dots) are shown. The shaded rectangle indicates the location of the 13q14
deletion that was present in three of the four CLL cases. Chromosome numbers
are listed below the four profiles. b, Frequency of substitutions in each CLL
tumour for the six possible classes of mutation. c, Distribution of the four
possibleNpAdinucleotides for theA toC transversion in each tumour genome,
compared with the expected distribution across the genome. The total number
of A toC substitutions per case is indicated at the top (**, P, 0.001).
Table 1 | Genes recurrently mutated in chronic lymphocytic leukaemia
Gene Protein Mutation Mutated
cases / total
Overall
frequency (%)
Frequency in
IGHV-unmutated (%)
Frequency in
IGHV-mutated (%)
NOTCH1 Notch 1 P2515Rfs*4
Q2503*
F2482Ffs*2
29/255
1/255
1/255
12.2 20.4 7
MYD88 Myeloid differentiation primary
response gene 88
L265P 9/310 2.9 0.8 5.6
XPO1 Exportin 1 E571K
E571G
3/165
1/165
2.4 4.6 0
KLHL6 Kelch-like 6 F49L/L65P
L90F
L58P/T64A/Q81P
3/160 1.8 0 4.5
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number of differentially expressed genes (n5 542, false discovery rate
,0.05; Supplementary Table 9). Likewise, in a gene-set analysis, we
found that there was significant differential expression of the
NOTCH1 signalling pathway12 and twometabolic pathways (oxidative
phosphorylation and glycolysis/gluconeogenesis). This is consistent
with the NOTCH1-mediated activation of multiple biosynthetic
routes in T acute lymphoblastic leukaemia13. When the differential
expression of individual genes from the NOTCH1 pathway was ana-
lysed, 23 of the 46 genes assigned to this pathway12 showed a significant
differential expression (P, 0.05) inNOTCH1-mutated CLL (Fig. 2d).
NOTCH1-mutated patients had a more advanced clinical stage at dia-
gnosis, more adverse biological features and an overall survival that
was significantly shorter than those with NOTCH1 unmutated (10-yr
overall survival: 21% versus 56%, P5 0.03; Fig. 2e, f). NOTCH1-
mutated CLL also underwent transformation into diffuse large B-cell
lymphoma more frequently than NOTCH1-unmutated CLL (7 of 31
cases, 23%, versus 3 of 224 cases, 1.3%; P, 0.001). The same IGHV
clonal rearrangement and NOTCH1mutation were found in the CLL
and corresponding transformed diffuse large B-cell lymphoma of the
four cases studied, indicating a clonal relationship of both components.
A recurrent mutation (p.L265P) in theMYD88 gene (Fig. 3a, b) was
also identified in 9 of 310 CLL patients (2.9%). During revision of this
manuscript, the same mutation has been identified in different lym-
phomas14, highlighting its relevance in the pathogenesis of lymphoid
neoplasias. This protein participates in the signalling pathways of
interleukin-1 and Toll-like receptors during the immune response15.
MyD88 immunoprecipitation from CLL cells with the p.L265P muta-
tion resulted in the co-immunoprecipitation of large amounts of
IRAK1, in contrast to cells lacking this mutation (Fig. 3c). Other effec-
tors of this signalling pathway, including STAT3, IkBa andNF-kB p65
subunit, showed higher phosphorylation in MYD88-mutated than in
unmutated CLL cells (Fig. 3d, e) and there was an increased DNA-
binding activity of NF-kB in MYD88-mutated cells (Supplementary
Fig. 4). These data support the hypothesis that the MYD88 p.L265P
mutation constitutes an activating mutation of this novel proto-
oncogene14,16. Stimulation of interleukin-1 receptor or Toll-like recep-
tors in MYD88-mutated CLL cells induced the secretion of 5-fold to
150-fold higher levels of interleukin 1 receptor antagonist (IL1RN, also
known as IL1RA), interleukin 6 and chemokine (C-Cmotif) ligands 2,
3 and 4 (CCL2, CCL3 and CCL4), when compared to the secretion of
these cytokines by MYD88-unmutated CLLs. Cytokine secretion was
elevated inMYD88-mutated cells in response to stimulation of at least
four of the eight TLRs tested. No response was observed in lympho-
cytes carrying the inactivatingMYD88mutation E52DEL (Fig. 3f and
Supplementary Fig. 5). The high production of these cytokines has
been implicated in the recruitment ofmacrophages andT lymphocytes
by CLL cells, creating a favourable niche for their survival17. Moreover,
activation of Toll-like receptors inCLL cells promotes the proliferation
of tumour cells and protects them from spontaneous apoptosis18.
Patients withMYD88-mutated CLL were diagnosed at a younger age
than those with wild-typeMYD88 (median 43 yr, range 38–63, versus
median 63 yr, range 27–94;P, 0.001) and the disease presentedwith a
more advanced clinical stage (Fig. 3g), although no differences were
observed in progression or survival rates. Notably, almost all patients
with the MYD88 p.L265P mutation (seven of the eight evaluated)
belonged to the IGHV-mutated group.
We also identified four cases with mutations in the same codon of
the exportin 1 gene (XPO1; p.E571K and p.E571G). Exportin 1 is
implicated in the nuclear export of proteins and mRNAs in yeast,
including members of the MAP kinase pathway19. The fact that the
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Figure 2 | Mutational and functional analysis of NOTCH1 in CLL.
a, Schematic representation of human NOTCH1, showing the main domains
and locations of the three different somatic mutations identified in CLL. NEC,
NOTCH1 extracellular subunit; NTM, NOTCH1 transmembrane subunit;
ICN, intracellular domain of NOTCH1; LNR, Lin-12 NOTCH repeats; RAM,
RAM domain; ANK, ankyrin repeat domain; PEST, PEST domain.
b, Electropherogram showing the heterozygous CT deletion recurrently
identified in CLL. c, Western blot showing NOTCH1 protein levels in CLL
cases with or without the NOTCH1 p.P2515Rfs*4mutation, and in Jurkat cells
as a control. The arrow indicates the band corresponding to the NTM; the large
arrowhead indicates the smaller band corresponding to the mutant form.
d, Heat map showing the 23 genes of the NOTCH1 pathway that are
differentially expressed in NOTCH1-mutated versus non-mutated CLL.
e, Distribution of disease stage (Binet), ZAP-70 expression status, CD38
expression status and IGHV mutational status (UM, unmutated IGHV) in
patients with or without mutations in NOTCH1 (*, P, 0.02; **, P, 0.01).
f, Actuarial probability of overall survival of CLL patients with mutated or
unmutated NOTCH1 (*, P5 0.03).
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same residue is mutated in four CLL cases and is part of a highly
conserved region (Supplementary Fig. 6) indicates that the mutation
affects XPO1 activity. Notably, all four cases with mutations in XPO1
belonged to the IGHV-unmutated subtype and two of them also had
the p.P2515Rfs*4 mutation in NOTCH1, indicating that both muta-
tions could have synergic effects in CLL development.
We identified three patients carrying a total of six mutations (F49L/
L65P, L90F and L58P/T64A/Q81P) in the gene encoding kelch-like
protein 6 (KLHL6), which is implicated in the formation of the germinal
centre during B cell maturation20. All six mutations were clustered
between residues 49 and 90 (Supplementary Fig. 7). The presence of
several pointmutations in cis, locatednear the transcriptional start site of
a gene that is highly expressed in the germinal centre, is a characteristic
feature of somatic hypermutation. In fact, all three patients hadCLLwith
mutated IGHV. Although somatic hypermutation occurs mainly in
IGHV regions, other proto-oncogenes, including BCL6, MYC and
PIM1, aremutated by somatic hypermutation in different lymphomas21.
However, only BCL6 has been previously shown to be hypermutated by
this mechanism in CLL21. Our data show that KLHL6 is probably also a
target of somatic hypermutation in IGHV-mutated patients, although its
precise contribution to the oncogenic process in CLL remains to be
determined.
In addition to these four genes, we identified a series of large geno-
mic alterations that were previously reported2. They included the dele-
tion, in three cases, of the 13q14 region22, and a 40-Mb deletion in
chromosome 6q14–q22 (Fig. 1a, Supplementary Fig. 1 and Sup-
plementary Table 5). Finally, in one patient we detected a p.P281R
mutation in the cyclin D2 gene (CCND2), which resulted in the accu-
mulation of cyclin D2 in tumour cells (Supplementary Fig. 8). This
finding, together with the high conservation of this residue and the
identification of mutations in the equivalent residue of cyclin D1
(CCND1) in endometrial cancer23, indicates that thisCCND2mutation
could be a driver contributing to the development of CLL in this
patient. The finding illustrates the putative relevance of non-recurrent
mutations for the pathogenesis of CLL.
The InternationalCancerGenomeConsortiumprojectwas founded
on the concept that sequencing of cancer genomes could reshape our
understanding of cancer biology, with direct implications for clinical
translation24. Our study of four CLL genomes underscores this trans-
formative potential, although additional studies will be necessary to
translate these findings to the clinic. We have identified four recur-
rentlymutated genes and provided novel insights into themechanisms
by which leukaemic cells recruit, instruct and coordinate a tumour
microenvironment. Currently, the biological identification of different
subgroups ofCLL is based onmarkers such as IGHVmutational status,
cytogenetics, ZAP-70 expression or CD38 expression, which are not
fundamental agents in the leukaemic process. The classification of
patients basedongenomic drivers of the disease is conceptually appeal-
ing, as shown by our demonstration thatNOTCH1 andMYD88muta-
tions identify distinct subgroups of patientswith particular clinical and
biological features. Furthermore, we provide functional evidence that
bothNOTCH1 andMYD88mutations are activating events andpoten-
tial therapeutic targets. The potential to personalize therapeutic
choices for patients on the basis of the genomic architecture of their
cancers is the long-term aspiration for studies such as this, combining
whole-genome sequencing, functional studies and clinical analysis of
patients with cancer.
METHODS SUMMARY
Four patients with CLL, who had given informed consent for sample collection
and analysis, were studied. Tumour samples were obtained before treatment and
tumour cells were separated from non-tumour cells by immunomagnetic deple-
tion of T cells, natural killer cells, monocytes and granulocytes (Supplementary
Information). Tumour cell purity was$98% as assessed by flow cytometry.
Normal blood cells from the same patient were obtained after treatment, resulting
in no detectable, or less than 0.05%, tumour cell contamination, as assessed by flow
cytometry. Additional samples from 363 patients were obtained for clinical valid-
ation. Protocols for long-insert and short-insert library construction and for mas-
sively parallel paired-end sequencing have been described elsewhere (ref. 25 and
Supplementary Information). Genotyping and copy number analysis were per-
formed using the Affymetrix SNP6.0, Agilent 1M and Illumina OmniQuad arrays
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Figure 3 | Mutational and functional analysis ofMYD88 inCLL. a, Multiple
sequence alignment ofMyD88 around themutated residue (arrow) in different
species. Cons., degree of conservation. b, Electropherogram showing the
recurrent heterozygous p.L265PMYD88mutation (arrow) detected in CLL.
c, Cell extracts from aMYD88-mutatedCLL (L265P) and aMYD88-unmutated
CLL (WT) were immunoprecipitated with anti-MyD88 antibody. The
immunoprecipitated and unbound fractions were analysed by western blot
using anti-IRAK1 and anti-MyD88 antibodies. d, Western blot analysis of
phosphorylated STAT3 (p-STAT3 (Tyr 705)) and total STAT3 in cell extracts
fromMYD88-mutated or unmutated CLL tumour cells. b-Actin was used as a
control to show equal loading. e, Western blots showing phosphorylated IkBa
(p-IkBa), total IkBa, phosphorylated p65 subunit of NF-kB (p-p65) and total
p65 subunit of NF-kB in cell extracts fromMYD88-mutated or unmutatedCLL
tumour cells. f, Heat map representing the cytokine levels secreted by B cells
from eight individuals after Toll-like receptor stimulation. Only the five
cytokines that showed the most significant differences betweenMYD88-
mutated andMYD88-unmutated CLL are shown. ‘E52DEL’ indicates B cells
from two patients with an inactivatingMYD88mutation, ‘WT’ corresponds to
tumour cells from CLL patients withoutMYD88 mutation and ‘L265P’
indicates tumour cells from patients carrying a mutatedMYD88. The
stimulation experiments for each of the Toll-like receptors (TLRs) are
represented in different colours. NS, no stimulus. g, Distribution of disease
stage (Binet), ZAP-70 expression status, CD38 expression status and IGHV
mutational status (UM, unmutated IGHV) in patients according to the
presence or absence of p.L265PMYD88 mutation (*, P, 0.03).
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on the same cases used for whole-genome sequencing. For the validation of can-
didate genes in a set of 169 additional CLL patients, we used a combination of PCR
amplification and Illumina sequencing in pooled samples, resulting in efficient
identification of germline and somatic mutations (Supplementary Information).
Sequencing data were aligned to the human reference genome (GRCh37) using
Burrows–Wheeler alignment (BWA)26 and somatic substitutions were identified
using Sidro´n, a probabilistic binomial model that uses genotyping data to calibrate
sequencing error per sample. Functional analyses of the identified mutations were
performed using cryopreserved primary tumour cells. For gene expression ana-
lysis, RNA was purified from tumour cells and analysed using the HU133 plus 2.0
GeneChip (Affymetrix). For immunoprecipitation and western blotting, CLL cell
extracts were prepared and detected using the indicated antibodies (Supplemen-
tary Information). For Toll-like receptor stimulation of CLL cells, the Human
TLR1–9 agonist kit (InvivoGen) was used.
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